Covidien issues guidance for its fiscal 2014 sales and earnings.
Covidien (NYSE:COV) CFO Charles Dockendorff gave investors a look at what the medical device company expects to see for its fiscal 2014 results.
Speaking at Mansfield, Mass.-based Covidien's annual investor meeting, Dockendorff said net sales for FY2014 are expected to grow between 2% and 5% over fiscal 2013.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Covidien launches a $21 million innovation center in South Korea, a country the medical device giant calls key to its international plans.
Massachusetts medical device maker Covidien (NYSE:COV) is opening the doors on a new Center of Innovation in South Korea, a country that the company calls "a key market in our global strategy."
Covidien warns customers in the U.S. and Bermuda that some of its Monoject syringes were mislabeled and not properly sterilized, prompting the company to recall 6 lots of the device.
Covidien (NYSE:COV) recalled some lots of its Monoject syringes after discovering a sterilization mishap and labeling problem.
The issues affected 6 lots in shipments that went out to customers in the U.S. and Bermuda, the Mansfield, Mass.-based medical products giant said.
A Delaware state jury finds that Covidien's ev3 subsidiary broke its deal for a $175 million milestone payment to Appriva Medical, awarding the milestone nut plus interest.
Covidien (NYSE:COV) is on the hook for a $175 million milestone owed by subsidiary ev3 Inc. to a company it acquired 11 years ago, plus another possible $100 million in interest, after a Delaware jury's decision last May.
A federal judge tosses 1 count of a patent infringement lawsuit filed by Covidien's Nellcor subsidiary against CAS Medical over patient monitoring technology.
SetPoint Medical raises $27 million, including contributions from Boston Scientific, Covidien and GlaxoSmithKline's new venture investing arm.
SetPoint Medical said Boston Scientific (NYSE:BSX) and Covidien (NYSE:COV) were among the participants in a $27 million funding round.